Fig. 6. Class II amplicons clinically phenocopy class I amplicons.

Kaplan Meier survival analysis of patients with MYCN-amplified neuroblastoma, comparing single-fragment vs. multi-fragment amplification (a), co-amplification of ODC1 vs. no co-amplification (b), co-amplification of ALK vs. no co-amplification (c), and class I amplicons vs. class II amplicons (d; N = 236 MYCN-amplified neuroblastomas; P value based on two-sided log-rank test). Source data are provided as a Source Data file.